Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy

Tumors typically lack canonical danger signals required to activate adaptive immunity and also frequently employ substantial immunomodulatory mechanisms that downregulate adaptive responses and contribute to escape from immune surveillance. Given the variety of mechanisms involved in shielding tumor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The FASEB journal 2024-05, Vol.38 (10), p.e23644-n/a
Hauptverfasser: Halpert, Matthew M., Burns, Briana A., Rosario, Spencer R., Withers, Henry G., Trivedi, Akshar J., Hofferek, Colby J., Gephart, Benjamin D., Wang, Haotong, Vazquez‐Perez, Jonathan, Amanya, Sharon B., Hyslop, Sean T., Yang, Jianhua, Kemnade, Jan O., Sandulache, Vlad C., Konduri, Vanaja, Decker, William K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 10
container_start_page e23644
container_title The FASEB journal
container_volume 38
creator Halpert, Matthew M.
Burns, Briana A.
Rosario, Spencer R.
Withers, Henry G.
Trivedi, Akshar J.
Hofferek, Colby J.
Gephart, Benjamin D.
Wang, Haotong
Vazquez‐Perez, Jonathan
Amanya, Sharon B.
Hyslop, Sean T.
Yang, Jianhua
Kemnade, Jan O.
Sandulache, Vlad C.
Konduri, Vanaja
Decker, William K.
description Tumors typically lack canonical danger signals required to activate adaptive immunity and also frequently employ substantial immunomodulatory mechanisms that downregulate adaptive responses and contribute to escape from immune surveillance. Given the variety of mechanisms involved in shielding tumors from immune recognition, it is not surprising that single‐agent immunomodulatory approaches have been largely unsuccessful in generating durable antitumor responses. Here we report a unique combination of immunomodulatory and cytostatic agents that recondition the tumor microenvironment and eliminate complex and/or poor‐prognosis tumor types including the non‐immunogenic 4T‐1 model of TNBC, the aggressive MOC‐2 model of HNSCC, and the high‐risk MYCN‐amplified model of neuroblastoma. A course of therapy optimized for TNBC cured a majority of tumors in both ectopic and orthotopic settings and eliminated metastatic spread in all animals tested at the highest doses. Immune responses were transferable between therapeutic donor and naïve recipient through adoptive transfer, and a sizeable abscopal effect on distant, untreated lesions could be demonstrated experimentally. Similar results were observed in HNSCC and neuroblastoma models, with characteristic remodeling of the tumor microenvironment documented in all model systems. scRNA‐seq analysis implicated upregulation of innate immune responses and antigen presentation in tumor cells and the myeloid cell compartment as critical early events. This analysis also highlighted the potential importance of the autonomic nervous system in the governance of inflammatory processes. The data indicate that the targeting of multiple pathways and mechanisms of action can result in substantial synergistic antitumor effects and suggest follow‐up in the neoadjuvant setting may be warranted. Here we describe a cocktail of immunomodulatory agents that, when injected intratumorally, leads to tumor resolution in multiple models of aggressive malignancy through microenvironmental remodeling of tumor cells, immune cells, and peripheral nerves.
doi_str_mv 10.1096/fj.202302675R
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3054432611</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3054432611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2944-f31ae34f33746896e97bcbf951610085322ef0e5299020e6ee33045261b0062c3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqWwZIu8ZJMyfsRJllBRQCpC4rGOnHRcuXIe2Amof09KC-xYjTRz5ujqEnLOYMogU1dmPeXABXCVxM8HZMxiAZFKFRySMaQZj5QS6YichLAGAAZMHZORSBORyoSPiX3sXWeNLrvGa0dtVfU10qpZ9k53tqlp23RYd1Z3GOiy97pwSD1WNoTt1da02gpa9_2ELtDGUL1aeRyAj2GpnV3Vui43p-TIaBfwbD8n5G1--zq7jxZPdw-z60VU8kzKyAimUUgjRCJVminMkqIsTBYzxQDSWHCOBjDmWQYcUCEKATLmihUAipdiQi533tY37z2GLh_CluicrrHpQy4gllIMPBvQaIeWvgnBo8lbbyvtNzmDfNtubtb5X7sDf7FX90WFy1_6p84BkDvg0zrc_G_L5y83nAs1hPkC6u2F3A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3054432611</pqid></control><display><type>article</type><title>Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Halpert, Matthew M. ; Burns, Briana A. ; Rosario, Spencer R. ; Withers, Henry G. ; Trivedi, Akshar J. ; Hofferek, Colby J. ; Gephart, Benjamin D. ; Wang, Haotong ; Vazquez‐Perez, Jonathan ; Amanya, Sharon B. ; Hyslop, Sean T. ; Yang, Jianhua ; Kemnade, Jan O. ; Sandulache, Vlad C. ; Konduri, Vanaja ; Decker, William K.</creator><creatorcontrib>Halpert, Matthew M. ; Burns, Briana A. ; Rosario, Spencer R. ; Withers, Henry G. ; Trivedi, Akshar J. ; Hofferek, Colby J. ; Gephart, Benjamin D. ; Wang, Haotong ; Vazquez‐Perez, Jonathan ; Amanya, Sharon B. ; Hyslop, Sean T. ; Yang, Jianhua ; Kemnade, Jan O. ; Sandulache, Vlad C. ; Konduri, Vanaja ; Decker, William K.</creatorcontrib><description>Tumors typically lack canonical danger signals required to activate adaptive immunity and also frequently employ substantial immunomodulatory mechanisms that downregulate adaptive responses and contribute to escape from immune surveillance. Given the variety of mechanisms involved in shielding tumors from immune recognition, it is not surprising that single‐agent immunomodulatory approaches have been largely unsuccessful in generating durable antitumor responses. Here we report a unique combination of immunomodulatory and cytostatic agents that recondition the tumor microenvironment and eliminate complex and/or poor‐prognosis tumor types including the non‐immunogenic 4T‐1 model of TNBC, the aggressive MOC‐2 model of HNSCC, and the high‐risk MYCN‐amplified model of neuroblastoma. A course of therapy optimized for TNBC cured a majority of tumors in both ectopic and orthotopic settings and eliminated metastatic spread in all animals tested at the highest doses. Immune responses were transferable between therapeutic donor and naïve recipient through adoptive transfer, and a sizeable abscopal effect on distant, untreated lesions could be demonstrated experimentally. Similar results were observed in HNSCC and neuroblastoma models, with characteristic remodeling of the tumor microenvironment documented in all model systems. scRNA‐seq analysis implicated upregulation of innate immune responses and antigen presentation in tumor cells and the myeloid cell compartment as critical early events. This analysis also highlighted the potential importance of the autonomic nervous system in the governance of inflammatory processes. The data indicate that the targeting of multiple pathways and mechanisms of action can result in substantial synergistic antitumor effects and suggest follow‐up in the neoadjuvant setting may be warranted. Here we describe a cocktail of immunomodulatory agents that, when injected intratumorally, leads to tumor resolution in multiple models of aggressive malignancy through microenvironmental remodeling of tumor cells, immune cells, and peripheral nerves.</description><identifier>ISSN: 0892-6638</identifier><identifier>ISSN: 1530-6860</identifier><identifier>EISSN: 1530-6860</identifier><identifier>DOI: 10.1096/fj.202302675R</identifier><identifier>PMID: 38738472</identifier><language>eng</language><publisher>United States</publisher><subject>ADORA3 ; Animals ; cancer immunotherapy ; Cell Line, Tumor ; Female ; HNSCC ; Humans ; Immunomodulation ; innate immune response ; innate signaling ; Mice ; Mice, Inbred C57BL ; MYCN‐amplified neuroblastoma ; Neuroblastoma - immunology ; Neuroblastoma - pathology ; Neuroblastoma - therapy ; proteasome ; RIG‐I ; STING ; TGF‐β ; TH1 polarization ; TLR ; TNBC ; tumor microenvironment ; Tumor Microenvironment - immunology</subject><ispartof>The FASEB journal, 2024-05, Vol.38 (10), p.e23644-n/a</ispartof><rights>2024 Federation of American Societies for Experimental Biology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2944-f31ae34f33746896e97bcbf951610085322ef0e5299020e6ee33045261b0062c3</cites><orcidid>0000-0003-0992-5838</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1096%2Ffj.202302675R$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1096%2Ffj.202302675R$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38738472$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Halpert, Matthew M.</creatorcontrib><creatorcontrib>Burns, Briana A.</creatorcontrib><creatorcontrib>Rosario, Spencer R.</creatorcontrib><creatorcontrib>Withers, Henry G.</creatorcontrib><creatorcontrib>Trivedi, Akshar J.</creatorcontrib><creatorcontrib>Hofferek, Colby J.</creatorcontrib><creatorcontrib>Gephart, Benjamin D.</creatorcontrib><creatorcontrib>Wang, Haotong</creatorcontrib><creatorcontrib>Vazquez‐Perez, Jonathan</creatorcontrib><creatorcontrib>Amanya, Sharon B.</creatorcontrib><creatorcontrib>Hyslop, Sean T.</creatorcontrib><creatorcontrib>Yang, Jianhua</creatorcontrib><creatorcontrib>Kemnade, Jan O.</creatorcontrib><creatorcontrib>Sandulache, Vlad C.</creatorcontrib><creatorcontrib>Konduri, Vanaja</creatorcontrib><creatorcontrib>Decker, William K.</creatorcontrib><title>Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy</title><title>The FASEB journal</title><addtitle>FASEB J</addtitle><description>Tumors typically lack canonical danger signals required to activate adaptive immunity and also frequently employ substantial immunomodulatory mechanisms that downregulate adaptive responses and contribute to escape from immune surveillance. Given the variety of mechanisms involved in shielding tumors from immune recognition, it is not surprising that single‐agent immunomodulatory approaches have been largely unsuccessful in generating durable antitumor responses. Here we report a unique combination of immunomodulatory and cytostatic agents that recondition the tumor microenvironment and eliminate complex and/or poor‐prognosis tumor types including the non‐immunogenic 4T‐1 model of TNBC, the aggressive MOC‐2 model of HNSCC, and the high‐risk MYCN‐amplified model of neuroblastoma. A course of therapy optimized for TNBC cured a majority of tumors in both ectopic and orthotopic settings and eliminated metastatic spread in all animals tested at the highest doses. Immune responses were transferable between therapeutic donor and naïve recipient through adoptive transfer, and a sizeable abscopal effect on distant, untreated lesions could be demonstrated experimentally. Similar results were observed in HNSCC and neuroblastoma models, with characteristic remodeling of the tumor microenvironment documented in all model systems. scRNA‐seq analysis implicated upregulation of innate immune responses and antigen presentation in tumor cells and the myeloid cell compartment as critical early events. This analysis also highlighted the potential importance of the autonomic nervous system in the governance of inflammatory processes. The data indicate that the targeting of multiple pathways and mechanisms of action can result in substantial synergistic antitumor effects and suggest follow‐up in the neoadjuvant setting may be warranted. Here we describe a cocktail of immunomodulatory agents that, when injected intratumorally, leads to tumor resolution in multiple models of aggressive malignancy through microenvironmental remodeling of tumor cells, immune cells, and peripheral nerves.</description><subject>ADORA3</subject><subject>Animals</subject><subject>cancer immunotherapy</subject><subject>Cell Line, Tumor</subject><subject>Female</subject><subject>HNSCC</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>innate immune response</subject><subject>innate signaling</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>MYCN‐amplified neuroblastoma</subject><subject>Neuroblastoma - immunology</subject><subject>Neuroblastoma - pathology</subject><subject>Neuroblastoma - therapy</subject><subject>proteasome</subject><subject>RIG‐I</subject><subject>STING</subject><subject>TGF‐β</subject><subject>TH1 polarization</subject><subject>TLR</subject><subject>TNBC</subject><subject>tumor microenvironment</subject><subject>Tumor Microenvironment - immunology</subject><issn>0892-6638</issn><issn>1530-6860</issn><issn>1530-6860</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqWwZIu8ZJMyfsRJllBRQCpC4rGOnHRcuXIe2Amof09KC-xYjTRz5ujqEnLOYMogU1dmPeXABXCVxM8HZMxiAZFKFRySMaQZj5QS6YichLAGAAZMHZORSBORyoSPiX3sXWeNLrvGa0dtVfU10qpZ9k53tqlp23RYd1Z3GOiy97pwSD1WNoTt1da02gpa9_2ELtDGUL1aeRyAj2GpnV3Vui43p-TIaBfwbD8n5G1--zq7jxZPdw-z60VU8kzKyAimUUgjRCJVminMkqIsTBYzxQDSWHCOBjDmWQYcUCEKATLmihUAipdiQi533tY37z2GLh_CluicrrHpQy4gllIMPBvQaIeWvgnBo8lbbyvtNzmDfNtubtb5X7sDf7FX90WFy1_6p84BkDvg0zrc_G_L5y83nAs1hPkC6u2F3A</recordid><startdate>20240531</startdate><enddate>20240531</enddate><creator>Halpert, Matthew M.</creator><creator>Burns, Briana A.</creator><creator>Rosario, Spencer R.</creator><creator>Withers, Henry G.</creator><creator>Trivedi, Akshar J.</creator><creator>Hofferek, Colby J.</creator><creator>Gephart, Benjamin D.</creator><creator>Wang, Haotong</creator><creator>Vazquez‐Perez, Jonathan</creator><creator>Amanya, Sharon B.</creator><creator>Hyslop, Sean T.</creator><creator>Yang, Jianhua</creator><creator>Kemnade, Jan O.</creator><creator>Sandulache, Vlad C.</creator><creator>Konduri, Vanaja</creator><creator>Decker, William K.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0992-5838</orcidid></search><sort><creationdate>20240531</creationdate><title>Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy</title><author>Halpert, Matthew M. ; Burns, Briana A. ; Rosario, Spencer R. ; Withers, Henry G. ; Trivedi, Akshar J. ; Hofferek, Colby J. ; Gephart, Benjamin D. ; Wang, Haotong ; Vazquez‐Perez, Jonathan ; Amanya, Sharon B. ; Hyslop, Sean T. ; Yang, Jianhua ; Kemnade, Jan O. ; Sandulache, Vlad C. ; Konduri, Vanaja ; Decker, William K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2944-f31ae34f33746896e97bcbf951610085322ef0e5299020e6ee33045261b0062c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>ADORA3</topic><topic>Animals</topic><topic>cancer immunotherapy</topic><topic>Cell Line, Tumor</topic><topic>Female</topic><topic>HNSCC</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>innate immune response</topic><topic>innate signaling</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>MYCN‐amplified neuroblastoma</topic><topic>Neuroblastoma - immunology</topic><topic>Neuroblastoma - pathology</topic><topic>Neuroblastoma - therapy</topic><topic>proteasome</topic><topic>RIG‐I</topic><topic>STING</topic><topic>TGF‐β</topic><topic>TH1 polarization</topic><topic>TLR</topic><topic>TNBC</topic><topic>tumor microenvironment</topic><topic>Tumor Microenvironment - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Halpert, Matthew M.</creatorcontrib><creatorcontrib>Burns, Briana A.</creatorcontrib><creatorcontrib>Rosario, Spencer R.</creatorcontrib><creatorcontrib>Withers, Henry G.</creatorcontrib><creatorcontrib>Trivedi, Akshar J.</creatorcontrib><creatorcontrib>Hofferek, Colby J.</creatorcontrib><creatorcontrib>Gephart, Benjamin D.</creatorcontrib><creatorcontrib>Wang, Haotong</creatorcontrib><creatorcontrib>Vazquez‐Perez, Jonathan</creatorcontrib><creatorcontrib>Amanya, Sharon B.</creatorcontrib><creatorcontrib>Hyslop, Sean T.</creatorcontrib><creatorcontrib>Yang, Jianhua</creatorcontrib><creatorcontrib>Kemnade, Jan O.</creatorcontrib><creatorcontrib>Sandulache, Vlad C.</creatorcontrib><creatorcontrib>Konduri, Vanaja</creatorcontrib><creatorcontrib>Decker, William K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The FASEB journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Halpert, Matthew M.</au><au>Burns, Briana A.</au><au>Rosario, Spencer R.</au><au>Withers, Henry G.</au><au>Trivedi, Akshar J.</au><au>Hofferek, Colby J.</au><au>Gephart, Benjamin D.</au><au>Wang, Haotong</au><au>Vazquez‐Perez, Jonathan</au><au>Amanya, Sharon B.</au><au>Hyslop, Sean T.</au><au>Yang, Jianhua</au><au>Kemnade, Jan O.</au><au>Sandulache, Vlad C.</au><au>Konduri, Vanaja</au><au>Decker, William K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy</atitle><jtitle>The FASEB journal</jtitle><addtitle>FASEB J</addtitle><date>2024-05-31</date><risdate>2024</risdate><volume>38</volume><issue>10</issue><spage>e23644</spage><epage>n/a</epage><pages>e23644-n/a</pages><issn>0892-6638</issn><issn>1530-6860</issn><eissn>1530-6860</eissn><abstract>Tumors typically lack canonical danger signals required to activate adaptive immunity and also frequently employ substantial immunomodulatory mechanisms that downregulate adaptive responses and contribute to escape from immune surveillance. Given the variety of mechanisms involved in shielding tumors from immune recognition, it is not surprising that single‐agent immunomodulatory approaches have been largely unsuccessful in generating durable antitumor responses. Here we report a unique combination of immunomodulatory and cytostatic agents that recondition the tumor microenvironment and eliminate complex and/or poor‐prognosis tumor types including the non‐immunogenic 4T‐1 model of TNBC, the aggressive MOC‐2 model of HNSCC, and the high‐risk MYCN‐amplified model of neuroblastoma. A course of therapy optimized for TNBC cured a majority of tumors in both ectopic and orthotopic settings and eliminated metastatic spread in all animals tested at the highest doses. Immune responses were transferable between therapeutic donor and naïve recipient through adoptive transfer, and a sizeable abscopal effect on distant, untreated lesions could be demonstrated experimentally. Similar results were observed in HNSCC and neuroblastoma models, with characteristic remodeling of the tumor microenvironment documented in all model systems. scRNA‐seq analysis implicated upregulation of innate immune responses and antigen presentation in tumor cells and the myeloid cell compartment as critical early events. This analysis also highlighted the potential importance of the autonomic nervous system in the governance of inflammatory processes. The data indicate that the targeting of multiple pathways and mechanisms of action can result in substantial synergistic antitumor effects and suggest follow‐up in the neoadjuvant setting may be warranted. Here we describe a cocktail of immunomodulatory agents that, when injected intratumorally, leads to tumor resolution in multiple models of aggressive malignancy through microenvironmental remodeling of tumor cells, immune cells, and peripheral nerves.</abstract><cop>United States</cop><pmid>38738472</pmid><doi>10.1096/fj.202302675R</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0003-0992-5838</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0892-6638
ispartof The FASEB journal, 2024-05, Vol.38 (10), p.e23644-n/a
issn 0892-6638
1530-6860
1530-6860
language eng
recordid cdi_proquest_miscellaneous_3054432611
source MEDLINE; Access via Wiley Online Library
subjects ADORA3
Animals
cancer immunotherapy
Cell Line, Tumor
Female
HNSCC
Humans
Immunomodulation
innate immune response
innate signaling
Mice
Mice, Inbred C57BL
MYCN‐amplified neuroblastoma
Neuroblastoma - immunology
Neuroblastoma - pathology
Neuroblastoma - therapy
proteasome
RIG‐I
STING
TGF‐β
TH1 polarization
TLR
TNBC
tumor microenvironment
Tumor Microenvironment - immunology
title Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T12%3A07%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multifactoral%20immune%20modulation%20potentiates%20durable%20remission%20in%20multiple%20models%20of%20aggressive%20malignancy&rft.jtitle=The%20FASEB%20journal&rft.au=Halpert,%20Matthew%20M.&rft.date=2024-05-31&rft.volume=38&rft.issue=10&rft.spage=e23644&rft.epage=n/a&rft.pages=e23644-n/a&rft.issn=0892-6638&rft.eissn=1530-6860&rft_id=info:doi/10.1096/fj.202302675R&rft_dat=%3Cproquest_cross%3E3054432611%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3054432611&rft_id=info:pmid/38738472&rfr_iscdi=true